ETHICS REVIEW APPROVAL

Medical Ethics Committee, The First Affiliated Hospital of Soochow University

Approval No.: (2024) Ethics Approval No. 134-2

Study Title	A Single-arm, Multi-center, Prospective Clinical Study of Mitoxantrone Hydrochloride Liposome Injection-based CMOP±R Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma		
Study Category	Clinical Research Project (Interventional Study) (including Real-World Research)		
Sponsor/Initiator	Department of Hematology, The First Affiliated Hospital of Soochow University		
Principal Investigator	Haiwen Huang	**Responsible Department**	Department of Hematology
Ethics Review Reference No.	2024134 (Continuing Review 2)	**Date Accepted**	2026-05-26
Review Date	2026-05-29	**Review Category**	Research Progress Report
Reviewers	Yitao Xu, Suning Chen	**Review Method**	Expedited Review
Review Decision	In accordance with applicable Chinese laws and regulations and international ethical guidelines, the Ethics Committee conducted an expedited review of the Research Progress Report (Initial Review) for this study. Decision: Approved to continue the study.		
Continuing Review Interval	**12 months**		

Committee Chair (Signature): 陈宣

Medical Ethics Committee, The First Affiliated Hospital of Soochow University (Official Seal)

Date: 2026-06-02

苏州大学附属第一医院 医学伦理委员会

Compliance Statement	The composition and operation of this Ethics Committee comply with GCP, applicable Chinese laws and regulations, and international ethical guidelines.

NOTICE TO THE INVESTIGATOR/SPONSOR:

1. Conduct the study in accordance with NMPA/GCP, the principles of the Declaration of Helsinki, applicable Chinese laws and regulations, and the protocol approved by the Ethics Committee, and protect the rights, interests, and safety of research participants.
2. Before the study begins, the sponsor/investigator shall complete clinical trial registration.
3. During the study, submit amendment applications, safety reports, protocol-deviation reports, study suspension/termination reports, and the Final Study Report as required.
4. In accordance with the annual/periodic continuing review interval specified in the Ethics Committee approval, whether or not the study has begun, submit an application for continuing review and a Research Progress Report one month before the continuing review due date.
5. During the study, promptly report to the Ethics Committee any protocol deviation or modification made to eliminate an immediate hazard to research participants; any change that increases risk to research participants or significantly affects conduct of the clinical study; all suspected unexpected serious adverse reactions; and any new information that may adversely affect the safety of research participants or conduct of the clinical study.
6. Upon completion of the clinical study, promptly submit the Final Study Report to the Ethics Committee for review.
7. This Ethics Review Approval takes effect on the date of issue and remains valid until the next continuing review is completed. The investigator/sponsor shall submit an application for continuing review at least one month before expiry. Following approval by the Ethics Committee, the validity of this approval will be extended.

Ethics Committee Address and Contact Details	Address: Room 1312, Comprehensive Building, Main Campus, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China Tel.: 0512-67972861, 0512-67972743; E-mail: sdfyec@163.com

LIST OF DOCUMENTS REVIEWED

1. Other Documents Requiring Explanation: "Research Progress Report"

2. Other: "Research Progress Report Checklist"